Objective: To investigate the expressions of GPR15 and FOXP3 in colorectal carcinoma(CRC) tissues and their clinical prognostic values. Methods : A total of 132 patients with CRC underwent radical surgery were collected. The control group selected the normal mucosal tissues more than 5 cm away from the edge of the cancer focus. Immunohistochemistry(Envision two-step method) was used to detect the expression levels of GPR15 and FOXP3 in CRC and adjacent tissues, and analyze their relationships with clinicopathological factors of colorectal cancer. Kaplan-Meier method was used to draw the survival curve to analyze the correlation between the expressions of GPR15 and FOXP3 and the survival prognosis of patients with CRC. The factors influencing prognosis of patients with colorectal cancer were analyzed by Cox regression. Results : The immunohistochemistry showed that the expression levels of GPR15 and FOXP3 in CRC were significantly higher than those in normal colorectal mucosal tissues(P<0.05). The expression of GPR15 in CRC tissues was correlated with location, nerve invasion and TNM stage; FOXP3 expression was correlated with sex(P<0.05).Both expressions were not significantly correlated with the clinicopathologic features of age, tumor size, differentiation degree, tissue type, depth of invasion, tumor budding, vascular invasion and lymph node metastasis. Correlation analysis showed that there was no significant correlation between GPR15 and FOXP3 expression(Kappa=-0.019,P>0.05). The survival prognosis of GPR15 positive group was significantly worse than that of negative group(log-rank: χ2=4.3,P=0.039);while the survival prognosis of FOXP3 positive group was significantly better than that of negative group(log-rank: χ2=7.3,P=0.007).Age ≤55 years, positive GPR15 and negative FOXP3 were independent risk factors for poor prognosis in patients with CRC(P<0.05). Conclusion The expression levels of GPR15 and FOXP3 in CRC are significantly higher than those in paracancer tissues, GPR15 and FOXP3 are expected to become new tumor markers for early screening, accurate treatment and prognosis assessment of CRC.

Objective:To compare the clinical efficacies of seton sequential treatment with different drugs for perianal fistula of active Crohn′s disease (CD) .Methods:Clinical data of 42 active CD patients with anal fistula undergoing seton sequential treatment in Suzhou Hospital of Traditional Chinese Medicine and Suzhou Hospital of Integrated Traditional Chinese and Western Medicine from January 2017 to December 2018 were retrospectively analyzed. According to seton sequential drugs, patients were divided into IFX group ( n = 11) , azathioprine group ( n = 14) and mesalazine group ( n = 17) . The pre- and post-operative symptoms, laboratory tests, disease activity indexes (CDAI and PDAI) , anal self-control (Wexner) score were compared among 3 groups. Results:Forty-two patients were followed up with a median time of 24 months (12-34 months) . The proportions of healing and effectiveness of anal fistula patients were 90.9%, 71.4% and 35.3% in the IFX group, azathioprine group and mesalazine group respectively. There was a significant difference in anal fistula healing among 3 groups ( P = 0.020) . The CDAI scores after treatment in IFX group, azathioprine group and mesalazine group were lower than those scores before treatment [ (96.66 ± 51.23) points vs (170.12 ± 52.67) points, (142.11 ± 79.68) points vs (196.82 ± 81.10) points, (179.91 ± 42.06) points vs (208.02 ± 42.60) points, all P<0.05]. There was a significant general difference in CDAI score among the 3 groups ( P = 0.005) . And the CDAI score after treatment in mesalazine group was obviously higher than that in IFX group ( P<0.05) . The PDAI scores after treatment in IFX group and azathioprine group were lower than those scores before treatment [ (1.71 ± 0.91) points vs (9.91 ± 3.53) points, (3.81 ± 2.40) points vs (10.07 ± 2.67) points, both P<0.05]. There was a significant general difference in PDAI score among IFX group, azathioprine group and mesalazine group [ (1.71 ± 0.91) points vs (3.81 ± 2.40) points vs (10.45 ± 2.84) points, P<0.001] and the PDAI scores after treatment gradually increased (all P<0.05) . Conclusions:Seton sequential treatment with drug is an effective method for the treatment of perianal fistula of active Crohn′s disease. IFX and azathioprine are suitable for the choice of sequential drugs.

Objective:To compare the clinical efficacies of seton sequential treatment with different drugs for perianal fistula of active Crohn′s disease (CD) .Methods:Clinical data of 42 active CD patients with anal fistula undergoing seton sequential treatment in Suzhou Hospital of Traditional Chinese Medicine and Suzhou Hospital of Integrated Traditional Chinese and Western Medicine from January 2017 to December 2018 were retrospectively analyzed. According to seton sequential drugs, patients were divided into IFX group ( n = 11) , azathioprine group ( n = 14) and mesalazine group ( n = 17) . The pre- and post-operative symptoms, laboratory tests, disease activity indexes (CDAI and PDAI) , anal self-control (Wexner) score were compared among 3 groups. Results:Forty-two patients were followed up with a median time of 24 months (12-34 months) . The proportions of healing and effectiveness of anal fistula patients were 90.9%, 71.4% and 35.3% in the IFX group, azathioprine group and mesalazine group respectively. There was a significant difference in anal fistula healing among 3 groups ( P = 0.020) . The CDAI scores after treatment in IFX group, azathioprine group and mesalazine group were lower than those scores before treatment [ (96.66 ± 51.23) points vs (170.12 ± 52.67) points, (142.11 ± 79.68) points vs (196.82 ± 81.10) points, (179.91 ± 42.06) points vs (208.02 ± 42.60) points, all P<0.05]. There was a significant general difference in CDAI score among the 3 groups ( P = 0.005) . And the CDAI score after treatment in mesalazine group was obviously higher than that in IFX group ( P<0.05) . The PDAI scores after treatment in IFX group and azathioprine group were lower than those scores before treatment [ (1.71 ± 0.91) points vs (9.91 ± 3.53) points, (3.81 ± 2.40) points vs (10.07 ± 2.67) points, both P<0.05]. There was a significant general difference in PDAI score among IFX group, azathioprine group and mesalazine group [ (1.71 ± 0.91) points vs (3.81 ± 2.40) points vs (10.45 ± 2.84) points, P<0.001] and the PDAI scores after treatment gradually increased (all P<0.05) . Conclusions:Seton sequential treatment with drug is an effective method for the treatment of perianal fistula of active Crohn′s disease. IFX and azathioprine are suitable for the choice of sequential drugs.